Cover Image
市場調查報告書

慢性阻塞性肺病(COPD):開發中產品分析

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 264708
出版日期 內容資訊 英文 529 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病(COPD):開發中產品分析 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018
出版日期: 2018年04月30日 內容資訊: 英文 529 Pages
簡介

慢性阻塞性肺病(COPD)是由於肺的呼氣吸氣不完全,呼吸困難造成的肺部疾病。由於空氣流入肺臟受阻,咳嗽,疲勞感,胸部疼痛的症狀便會與時俱增,同時也增加了併發症。第一個風險要素是吸煙,但化學物質及大氣污染等也是COPD惡化的要因。可以禁煙及服用其他治療藥來控制病情。

本報告提供慢性阻塞性肺病(COPD)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性阻塞性肺病(COPD)概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

開發被休止的產品

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10371IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 39, 24, 1, 88, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 7
  • Chronic Obstructive Pulmonary Disease (COPD) - Overview 8
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development 9
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 32
  • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 48
  • Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles 95
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 461
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 490
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 497
  • Appendix 508

List of Tables

  • Table 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 9: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 10: Products under Development by Companies, H1 2018
  • Table 11: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 12: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 13: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 14: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 15: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 16: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 17: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 18: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 19: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 20: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 21: Products under Development by Universities/Institutes, H1 2018
  • Table 22: Number of Products by Stage and Target, H1 2018
  • Table 23: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 24: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Table 25: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Table 26: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
  • Table 27: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 28: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 29: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Table 30: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Table 31: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
  • Table 32: Number of Products by Stage and Route of Administration, H1 2018
  • Table 33: Number of Products by Stage and Molecule Type, H1 2018
  • Table 34: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2018
  • Table 35: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018
  • Table 36: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals Inc, H1 2018
  • Table 37: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2018
  • Table 38: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018
  • Table 39: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2018
  • Table 40: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2018
  • Table 41: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2018
  • Table 42: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2018
  • Table 43: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp, H1 2018
  • Table 44: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H1 2018
  • Table 45: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arch Biopartners Inc, H1 2018
  • Table 46: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2018
  • Table 47: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H1 2018
  • Table 48: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2018
  • Table 49: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H1 2018
  • Table 50: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioblue Technologies Inc, H1 2018
  • Table 51: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H1 2018
  • Table 52: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Table 53: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2018
  • Table 54: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics Inc, H1 2018
  • Table 55: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group Inc, H1 2018
  • Table 56: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H1 2018
  • Table 57: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2018
  • Table 58: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by China Resources Pharmaceutical Group Ltd, H1 2018
  • Table 59: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cipla Ltd, H1 2018
  • Table 60: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2018
  • Table 61: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H1 2018
  • Table 62: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H1 2018
  • Table 63: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
  • Table 64: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Table 65: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2018
  • Table 66: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H1 2018
  • Table 67: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H1 2018
  • Table 68: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H1 2018
  • Table 69: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Evaxion Biotech ApS, H1 2018
  • Table 70: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2018
  • Table 71: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H1 2018
  • Table 72: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Table 73: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top